Skip to main content
Terug
Watch Compare

Jasper Therapeutics, Inc.

Datakwaliteit: 83%
Ook genoteerd als JSPRW Nasdaq
JSPR
Nasdaq Manufacturing Chemicals
€ 0,82
▲ € 0,12 (16,48%)
Marktkapitalisatie: 23,06 M
Prijs
€ 0,82
Marktkapitalisatie
23,06 M
Dagbereik
€ 0,71 — € 0,85
52-Weeksbereik
€ 0,62 — € 7,19
Volume
1.139.874
Openen € 0,72
50D / 200D Gem.
€ 1,27
35,37% below
50D / 200D Gem.
€ 2,26
63,62% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -77,16 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-432,26%
Onder sectorgemiddelde (-53,41%)
ROIC-212,42%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio2,59
Interest CoverageN/A

Waardering

PE (TTM)
-0,30
Boven sectorgemiddelde (-1,48)
P/B Ratio1,99
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,3 -1,5
P/B 2,0 1,6
ROE % -432,3 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

ETFs Holding This Stock

SURI logo SURI Simplify Propel Opportunities ETF
2,10% weight
AVSCX AVSCX
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -75,80 M
ROE -432,26% ROA -145,86%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -77,16 M
ROIC -212,42% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2,59
Interest Coverage N/A Asset Turnover N/A
Working Capital 33,52 M Tangible Book Value 11,57 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,30 Forward P/E N/A
P/B Ratio 1,99 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -334,64%
Market Cap 23,06 M Enterprise Value -27,84 M
Per Share
EPS (Diluted TTM) -3,95 Revenue / Share N/A
FCF / Share -2,76 OCF / Share -2,76
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 101,79%
SBC-Adj. FCF -84,21 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -75,80 M -71,27 M -64,47 M -37,69 M -30,64 M
EPS (Diluted) -3,95 -4,89 -6,18 -1,03 —
Gross Profit — — — — —
Operating Income -83,88 M -76,24 M -68,86 M -51,20 M -36,83 M
EBITDA — — — — —
R&D Expenses 63,10 M 55,82 M 51,79 M 34,63 M 25,42 M
SG&A Expenses — — — — —
D&A 1,06 M 1,37 M 1,11 M 975.000,0 377.000,0
Interest Expense — — -246.000,0 — -80.000,0
Income Tax 2.000,0 2.000,0 — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 35,78 M 79,90 M 94,89 M 48,36 M 93,65 M
Total Liabilities 31,63 M 18,23 M 16,45 M 12,37 M 24,14 M
Shareholders' Equity 4,15 M 61,67 M 78,44 M 35,99 M 69,52 M
Total Debt — — — — —
Cash & Equivalents 28,69 M 71,64 M 86,89 M 38,25 M 84,70 M
Current Assets 34,65 M 75,81 M 88,94 M 41,73 M 87,83 M
Current Liabilities 13,20 M 15,24 M 12,37 M 7,07 M 8,02 M